High-quality solutions underpinned by scientific, clinical, and economic evidence

Rhythm’s technologies have the potential to be an important contributor to the betterment of early cancer screening and patient outcomes globally.

Early detection of cancer saves lives

Rhythm Biosciences

Rhythm Biosciences (ASX:RHY) is transforming cancer diagnostics through innovative technologies that predict, detect, characterise, and support early intervention. Our flagship blood-based technology ColoSTAT revolutionises bowel cancer screening, while geneType provides crucial risk assessment across multiple cancer types.

We’re creating a comprehensive approach to understanding cancer risk, enabling earlier detection when treatment is most effective. Through our scientific innovation and commitment to accessible testing solutions, we’re aiming to reduce healthcare costs and ultimately save lives.

Our Products
Rhythm is developing high-quality solutions underpinned by scientific, clinical, and economic evidence to better detect cancer early and help manage disease characterisation and treatment.

The Company has a rich and rapidly maturing product portfolio which includes its blockbuster product ColoSTAT® for the early detection of colorectal cancer, and the geneType platform – a world-leading personalised predictive test portfolio that uses a unique combination of genomic and clinical information to predict risk of chronic disease development.